| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/04/2004 | EP1441689A1 Solid oral compositions |
| 08/04/2004 | EP1441667A1 Improved endoprosthetic device |
| 08/04/2004 | EP1441656A1 Method and apparatus for production of a skin graft and the graft produced thereby |
| 08/04/2004 | EP1441635A2 Sterile, breathable patch for treating wound pain |
| 08/04/2004 | EP1441602A1 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent |
| 08/04/2004 | EP1441589A2 Stable liquid pharmaceutical formulation of igg antibodies |
| 08/04/2004 | EP1313772B1 New cross-linked derivatives of hyaluronic acid |
| 08/04/2004 | EP1278511B1 Use of a lacrophyl preparation in eye-drops containing therapeutically active compounds |
| 08/04/2004 | EP1237423B1 Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
| 08/04/2004 | EP1228032B1 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 08/04/2004 | EP1208143B1 Film coatings and film coating compositions based on polyvinyl alcohol |
| 08/04/2004 | EP1150658B1 Method for controlling liposome size |
| 08/04/2004 | EP1143968B9 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 08/04/2004 | EP1140021B1 Improved formulation for topical non-invasive application in vivo |
| 08/04/2004 | EP1077065B1 Controlled release formulations |
| 08/04/2004 | EP0790835B1 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| 08/04/2004 | EP0740708B1 Design of drugs involving receptor-ligand-dna interactions |
| 08/04/2004 | CN1518595A 修饰的精氨酸脱亚胺酶 Modified arginine deiminase |
| 08/04/2004 | CN1518592A Male contraceptives |
| 08/04/2004 | CN1518573A Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for preparation of the same |
| 08/04/2004 | CN1518567A Linear block polymer |
| 08/04/2004 | CN1518479A Stabilization and terminal sterilization of phospholipid formulations |
| 08/04/2004 | CN1518469A Dermatological formulations |
| 08/04/2004 | CN1518462A Pharmaceutical formulation |
| 08/04/2004 | CN1518461A Medicinal compositions |
| 08/04/2004 | CN1518452A Oral delivery of macromolecules |
| 08/04/2004 | CN1518449A Pediatric formulation of gatifloxacin |
| 08/04/2004 | CN1518446A Repinotan kit |
| 08/04/2004 | CN1518443A Stable pharmaceutical composition of pravastatin |
| 08/04/2004 | CN1518442A Pharmaceutical compositions comprising cyclosporin |
| 08/04/2004 | CN1518441A Particles for inhalation having rapid release properties |
| 08/04/2004 | CN1517395A Hydroxy propyl-beta-cyclodextrin inclusion compound of anisolene and its preparation and preparation method |
| 08/04/2004 | CN1517394A Water-solubility natural film and its proparation method |
| 08/04/2004 | CN1517126A Drug compastion with thrombolysis, anti-inflammatory and cell protective function |
| 08/04/2004 | CN1517090A Animal use suspensoid injection or emulsion containing antibacterial medicine |
| 08/04/2004 | CN1160457C Recombinant mistletoe lectin (rML) |
| 08/04/2004 | CN1160129C Process for preparing medicines with no or low loxic by-effect on gastointestinal system |
| 08/04/2004 | CN1160128C Antiviral formulations comprising propylene glycol and isopropyl alkanoic acid ester |
| 08/04/2004 | CN1160127C Powdery pernasal compositions |
| 08/04/2004 | CN1160079C Bubbling enteric coated preparations |
| 08/04/2004 | CN1160076C Pharmaceutical composition comprising bisphosphonic acid |
| 08/04/2004 | CN1160064C Selective antibiotic composition |
| 08/04/2004 | CN1160062C Pharmaceutical formulation comprising omeprazole |
| 08/04/2004 | CN1160061C Core tablet for controlled release of gliclazide after oral administration |
| 08/04/2004 | CN1160060C Compressed compositions comprising clarified xanthan gum |
| 08/04/2004 | CN1160059C Process of generating submicron particles of water-insuluble compounds |
| 08/04/2004 | CN1160057C Microemlusions used as carriers for administration of active compounds |
| 08/04/2004 | CN1160056C Intravaginal clindamycin ovule composition |
| 08/04/2004 | CN1160053C Niacinamide compsns. with reduced tack |
| 08/03/2004 | US6770797 Inducing prolonged in vivo gene expression in a mammal for inhibiting alzheimer's disease associated neuronal cell death |
| 08/03/2004 | US6770746 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 08/03/2004 | US6770740 Crosslinked DNA condensate compositions and gene delivery methods |
| 08/03/2004 | US6770670 Injectable composition |
| 08/03/2004 | US6770625 Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| 08/03/2004 | US6770623 Stabilized teriparatide solutions |
| 08/03/2004 | US6770621 Polyacid glycopeptide derivatives |
| 08/03/2004 | US6770619 Lung surfactant compositions with dynamic swelling behavior |
| 08/03/2004 | US6770478 Erythrocytic cells and method for preserving cells |
| 08/03/2004 | US6770368 Solid phase; drugs or foods; concurrent spray drying |
| 08/03/2004 | US6770305 Oral administration to counteract dehydration resulting from vomiting, diarrhea, physical exercise or illness; especially suitable for infants, small children and the elderly; water, sodium, potassium, citrate, carbonate and structuring |
| 08/03/2004 | US6770300 Rapidly decomposing chitosan-based pellets |
| 08/03/2004 | US6770299 Lipid matrix-drug conjugates particle for controlled release of active ingredient |
| 08/03/2004 | US6770296 Hydrophilic core overcoated with hydrophobic hot melt lipid; for water soluble vitamins |
| 08/03/2004 | US6770294 Wrapping film for drugs, cosmetics, foods |
| 08/03/2004 | US6770293 Soft capsules comprising polymers of vinyl esters and polyethers, the use and production thereof |
| 08/03/2004 | US6770292 Pharmaceutical compositions for oral administration |
| 08/03/2004 | US6770290 Amphotericin b liposomes formed have markedly reduced toxicity |
| 08/03/2004 | US6770282 Purified nucleic acid molecule encoding rabies glycoprotein g, complexed with a cationic lipid comprising tetramethyltetraalkyl spermine analog lipid; enhances immune response compared to administration of a naked dna vaccine |
| 08/03/2004 | US6770276 Insulin-containing medicament for peroral application and method for the production thereof |
| 08/03/2004 | CA2310207C Topical zinc compositions and methods of use |
| 08/03/2004 | CA2271095C Stabilised pharmaceutical compositions, with quinupristine and dalfopristine base and their preparation |
| 08/03/2004 | CA2208155C Sugarfree hard coatings and a method for producing them |
| 08/03/2004 | CA2121065C External anti-inflammatory and analgesic plaster preparation |
| 08/03/2004 | CA2110161C Medetomidine preparations for transdermal administration |
| 08/03/2004 | CA2041093C A pharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active substance |
| 07/29/2004 | WO2004064109A2 Water soluble metal and semiconductor nanoparticle complexes |
| 07/29/2004 | WO2004063388A2 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 07/29/2004 | WO2004063250A1 Thiol-selective water-soluble polmer derivatives |
| 07/29/2004 | WO2004063216A1 Conjugate for retention in blood and cancer tissue-specific drug delivery |
| 07/29/2004 | WO2004063213A2 Peptides which target tumor and endothelial cells, compositions and uses thereof |
| 07/29/2004 | WO2004062693A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
| 07/29/2004 | WO2004062692A1 Formulation of poorly water-soluble active substances |
| 07/29/2004 | WO2004062691A1 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 07/29/2004 | WO2004062689A1 Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
| 07/29/2004 | WO2004062673A1 Anti-protozoal compositions comprising diclazuril |
| 07/29/2004 | WO2004062646A1 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/29/2004 | WO2004062628A2 Gilsonite derived pharmaceutical delivery compositions and methods |
| 07/29/2004 | WO2004062614A2 Carbohydrate conjugates to prevent abuse of controlled substances |
| 07/29/2004 | WO2004062603A2 Methods of treating lung diseases |
| 07/29/2004 | WO2004062602A2 Compositions and methods for targeted biological delivery of molecular carriers |
| 07/29/2004 | WO2004062588A2 Water-soluble polymeric bone-targeting drug delivery system |
| 07/29/2004 | WO2004062569A2 Cardiolipin compositions their methods of preparation and use |
| 07/29/2004 | WO2004062564A2 Sedative non-benzodiazepine formulations |
| 07/29/2004 | WO2004050123A3 Concentrated liquid valdecoxib composition |
| 07/29/2004 | WO2004050011A3 High enantiomeric purity dexanabinol for pharmaceutical copositions |
| 07/29/2004 | WO2004047713A3 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 07/29/2004 | WO2004045645A3 A bacteriophage preparation of enhanced stability by application of a block copolymer of ethylene oxide and propylene oxide |
| 07/29/2004 | WO2004045533A3 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 07/29/2004 | WO2004043993A3 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use |
| 07/29/2004 | WO2004041297A3 Modified cytokines for use in cancer therapy |